Benzinga | Apr 21, 2021 07:34AM EDT

Horizon Therapeutics Collaboration Partner HemoShear Therapeutics Identifies Second Drug Target For Gout

HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has identified a second drug target for the treatment of gout under its collaboration with Horizon Therapeutics plc (NASDAQ:HZNP) that was established in January 2019. Leveraging its proprietary REVEAL-Tx(tm) disease modeling platform, HemoShear has earned two milestone payments to date in accordance with the Horizon exclusive drug discovery agreement. Each milestone acknowledges the validation of a novel drug target and its advancement to a subsequent stage in Horizon's early discovery pipeline.